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OBJECTIVES We sought to determine the overall prognostic importance of left ventricular hypertrophy
(LVH) among patients with coronary artery disease (CAD), as well as to determine whether
this risk varies as a function of race or gender.
BACKGROUND Left ventricular hypertrophy is more prevalent among blacks and women than their
counterparts. Blacks and women also have higher mortality with coronary disease.
METHODS We studied records of 2,461 patients (19% black, 42% women) diagnosed with CAD at
cardiac catheterization between 1990 and 1998 from a single academic center. Left ventricular
hypertrophy was defined using standard echocardiographic measures. Cox proportional
hazards models were used for adjusted survival analyses. Mean patient follow-up was three
years.
RESULTS Patients with LVH were older (68 vs. 65 years, p  0.01), more often women (54% vs. 36%,
p 0.01), and black (25% vs. 16%, p 0.01), and had higher unadjusted three-year mortality
rates than patients without LVH (42% vs. 34%, p  0.01). Left ventricular hypertrophy
remained an independent predictor of mortality after adjusting for other clinical risk factors
(hazard ratio 1.56, 95% confidence interval 1.35 to 1.80) with prognostic importance
equivalent to that of left ventricular ejection fraction. Although the relative risk of LVH did
not vary by race or gender, the attributable risk of LVH was greater in blacks and women.
CONCLUSIONS Clinicians should consider the prognostic importance of LVH when assessing risk in patients
with CAD. Because LVH is more common among black and women patients with CAD, it
partially accounts for racial and gender differences in survival. (J Am Coll Cardiol 2003;41:
949–54) © 2003 by the American College of Cardiology Foundation
Estimating long-term prognosis is an important component
in determining appropriate care for patients with coronary
artery disease (CAD). Risk assessment has traditionally
been based on the patient’s demographics (age, gender,
race), disease severity (extent of coronary occlusions, left
ventricular [LV] ejection fraction), and other cardiac risk
factors (diabetes mellitus, hypertension, smoking status,
hyperlipidemia). Beyond this traditional risk assessment,
investigators have identified left ventricular hypertrophy
(LVH), defined by echocardiography, as an additional
predictor of cardiovascular and all-cause mortality (1–4).
Despite such evidence, in practice clinicians neither rou-
tinely assess for LVH nor adjust for it when they estimate a
patient’s prognosis (5–7).
Additionally, LVH is more prevalent in blacks than
whites and in women than men (2–4,8), and prior studies
have postulated that the relative risk (RR) associated with it
may be greater in these subgroups (2,3,9). Combined, the
differential effects of LVH could be an important explana-
tion for known racial or gender differences in long-term
survival among patients with coronary disease.
The primary purpose of this study was to determine the
incremental prognostic importance of LVH in a large,
contemporary, racially diverse population of patients with
CAD. We explored whether the RR associated with LVH
varied as a function of patient race or gender, and we
examined to what extent LVH explained survival differences
between blacks and whites and/or between women and
men.
METHODS
Study patients. All patients underwent an initial cardiac
catheterization at Duke University Medical Center between
1990 and 1998 and had an echocardiogram performed
within one month, during which left ventricular mass
(LVM) and body surface area (BSA) indices were obtained.
Patients were eligible for the study if they were found to
have significant obstructive coronary disease as we defined.
Patients were excluded from our analysis if their race was
classified as other than black or white.
Cardiac catheterization. Patients underwent standard left
heart cardiac catheterization, and coronary cineangiograms
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were obtained in the standard projections. Significant CAD
was defined as a 75% reduction in the cross-sectional
diameter of a major coronary artery. The extent of CAD
was summarized with the Coronary Artery Disease Index, a
composite score that takes into account both disease loca-
tion and severity (10).
Echocardiography. Echocardiograms were performed us-
ing standard two-dimensional measurements. The LV
measurements included interventricular septal thickness at
end-diastole (IVSTd), the posterior wall thickness at end-
diastole (PWTd), and left ventricular internal dimension at
end-diastole (LVIDd). Corrected LV mass was calculated
using this formula (11): LVM 1.04 [(IVSTd LVIDd
PWTd)
3  (LVIDd)
3] [(0.8  0.6)]. Left ventricular mass
index (LVMI, g/m2) was calculated as LVM/BSA (12).
Finally, the diagnostic criteria for LVH using LVMI (g/m2)
were 134 g/m2 for men and 110 g/m2 for women,
representing the gender-specific 97th percentile of a previ-
ously published reference in a normal population (13).
Data collection and follow-up. Baseline clinical and de-
mographic information and informed consent were ob-
tained by a physician at the time of cardiac catheterization
(14,15). Patients were contacted by telephone six months
after the index catheterization and annually thereafter.
Follow-up was complete in 95% of the patients. The
National Death Index was used to search for patients we
were unable to locate (16).
Statistical analysis. Medians and interquartile ranges
(25th to 75th percentile) were used to describe baseline
characteristics in continuous variables, and percentages were
used to describe discrete variables. The associations between
these characteristics and LVH were analyzed using a chi-
square or Wilcoxon rank-sum test as appropriate.
We analyzed LVH both as a continuous and as a
dichotomous variable using the previously described cutoff
points. For descriptive purposes, the dichotomous results
were presented; however, the results of LVH on overall
prognosis and by race and gender were similar regardless of
the method of analysis of the variable. Because of censoring,
we considered survival to three years the primary end point.
The incremental effect of LVH on the three-year survival
rate was performed using a Cox survival model that adjusted
for known prognostic baseline indicators including age,
gender, race, coronary artery disease severity (CAD index),
LV ejection fraction, diabetes mellitus, chronic obstructive
pulmonary disease, peripheral vascular disease, mitral insuf-
ficiency, and congestive heart failure (17). Hypertension was
also considered for inclusion in this model but was not
found to be a significant independent predictor after adjust-
ing for other factors. We formally analyzed whether the RR
of LVH varied by race or gender by testing the significance
of interaction terms (LVH by race, LVH by gender) in the
Cox survival model. Risk ratios (hazards ratio) and the 95%
confidence intervals (CIs) were derived from the Cox
coefficients and associated standard error. We calculated the
population attributable risk (PAR) by race and by gender,
which takes into account both the prevalence of LVH and
the RR of death associated with LVH, using the formula:
PAR  LVH prevalence (RR  1)/[LVH prevalence
(RR  1)  1].
RESULTS
Baseline characteristics. We identified 4,953 patients who
had significant CAD at catheterization and underwent
echocardiography within one month of catheterization. Of
these, 2,461 patients had echocardiographic measurements
necessary for LVM calculation, had BSA information, and
were either black or white. Comparison of patients included
in our study versus those excluded because of missing
echocardiographic information revealed no significant dif-
ferences in baseline clinical risk factors.
Cumulative LVM by BSA ranged from 94 to 156 g/m2.
Using standard echocardiographic criteria, LVH was iden-
tified in 35% of our CAD population (Table 1). Patients
with LVH were slightly older (68 vs. 65 years) and more
likely to have hypertension (75% vs. 61%), diabetes (39% vs.
31%), and peripheral vascular disease (25% vs. 20%) than
patients without LVH.
LVH as a risk factor for all-cause mortality. The mean
follow-up duration was 3  2 years. The overall unadjusted
and adjusted survival rates were significantly lower among
patients with LVH compared with patients having normal
LVM (Fig. 1). Unadjusted survival rates at one, three, and
five years were 75%, 56%, and 42% respectively for those
with LVH versus 88%, 76%, and 67% (p  0.01) respec-
tively for those without LVH. The unadjusted risk ratio for
patients with LVH at three years was 2.1 (95% CI 1.96 to
2.23).
After adjusting for demographic, clinical, and angio-
graphic risk factors (Table 2), LVH remained an indepen-
dent predictor of three-year mortality (RR 1.56, 95% CI
1.35 to 1.80). Ranking these risk factors by their overall
contribution to model, we found LVH to be the third most
powerful prognostic factor, after patient age and coronary
disease severity (Table 2).
Abbreviations and Acronyms
BSA  body surface area
CAD  coronary artery disease
CI  confidence interval
HR  hazard ratio
IVSTd  interventricular septal thickness at end-diastole
LV  left ventricular
LVH  left ventricular hypertrophy
LVIDd  left ventricular internal dimension at end-
diastole
LVM  left ventricular mass
LVMI  left ventricular mass index
PAR  population attributable risk
PWTd  posterior wall thickness at end-diastole
RR  relative risk
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LVH risk as a function of race or gender. We also
assessed whether the RR of LVH varied with patient race or
gender. Although LVH was more common among blacks
than whites (46% vs. 33%, p  0.01) and among women
than men (45% vs. 28%, p 0.01), its impact on unadjusted
and adjusted survival estimates in these groups was similar
(Figs. 2 and 3). The adjusted LVH hazard ratio (HR) was
1.54 (95% CI 1.11 to 2.13) in blacks versus 1.56 (95% CI
1.33 to 1.84) in whites. In women, the adjusted LVH HR
was 1.48 (95% CI 1.20 to 1.83) versus 1.63 (95% CI 1.34 to
1.98) in men. Additionally, formal statistical testing re-
vealed no significant interaction between LVH and race or
gender. Although blacks and women had similar RR, their
higher prevalence of LVH led to differences in the PAR.
The PAR was 20% among blacks versus 16% among whites,
and 18% among women versus 15% among men.
Prognostic implications for higher mortality among
blacks and women. In the overall CAD population, blacks
had higher unadjusted mortality rates than whites at three
years: 43% versus 23% for those with LVH and 30% versus
23% for those without. After adjusting for traditional
clinical risk factors, blacks continued to have higher mor-
tality risk (HR 1.16, 95% CI 0.98 to 1.37). However, after
adjusting for traditional factors and LVH, the mortality
differences narrowed (HR 1.10, 95% CI 0.93 to 1.31).
Women also had higher unadjusted three-year mortality
rates than men: 40% versus 24% for those with LVH and
30% versus 21% for those without. After adjusting for
baseline traditional risk factors, women and men had similar
three-year mortality rates (HR 1.01, 95% CI 0.88 to 1.17).
Interestingly, after accounting for traditional risk factors and
LVH, women actually had a trend toward lower long-term
mortality than men did (HR 0.93, 95% CI 0.81 to 1.08).
DISCUSSION
Clinical practice guidelines have not traditionally empha-
sized the need to consider LVH in the risk assessment of
those with coronary disease (6,7). However, our contempo-
rary study confirmed that the presence of LVH had impor-
tant prognostic implications in a large, racially diverse
patient cohort. Although its relative impact on prognosis
was similar across race and gender, differences in LVH
prevalence can partly explain why blacks and women with
coronary disease have higher mortality rates than their
counterparts.
The Framingham Heart Study was one of the first
investigations to identify the prognostic importance of LVH
(4). M-mode echocardiography was used to classify LVH
status in 3,220 subjects without baseline cardiac disease.
After adjusting for cardiac risk factors, all-cause mortality
risk with LVH was 1.49 (95% CI 1.14 to 1.94) in men and
2.01 (95% CI 1.44 to 2.81) in women. However, this study
was limited to a predominately white patient population and
reflects care patterns from the 1980s.
Liao et al. (2) studied echocardiographic-measured LVH
in a predominately black cohort undergoing concomitant
cardiac catheterization between 1983 and 1991. After ad-
justing for baseline risk factors and angiographic findings,
these investigators also found that LVH doubled a patient’s
five-year mortality risk. They further concluded that the RR
of LVH was higher in women than men, particularly among
those patients with insignificant coronary disease. They also
proposed that LVH may play a differential role in blacks
versus whites, but their study lacked an adequate represen-
tation of whites to test this hypothesis (3).
Our study confirms and expands our understanding of the
Table 1. Baseline Characteristics of the Study Population
Variable
LVH
(n  862)
Non-LVH
(n  1,599) p Value
Age (yrs) 68 (60,75) 65 (56,73)  0.01
Blacks 25 16  0.01
Female 54 36  0.01
Hypertension 75 61  0.01
Diabetes mellitus 39 31  0.01
Hyperlipidemia 50 52 0.37
Peripheral vascular disease 25 20  0.01
Chronic obstructive pulmonary disease 9 11 0.20
Ejection fraction 40 (28,55) 50 (38,60)  0.01
NYHA class IV congestive heart failure 20 9  0.01
Severe mitral insufficiency, 3  13 7  0.01
Severe mitral insufficiency, 4  6 4  0.01
Number of diseased vessels  0.01
1 vessel 30 36
2 vessel 26 26
3 vessel 44 38
Treatment  0.01
Medicine 63 49
PTCA 19 31
CABG 18 20
CABG  coronary artery bypass graft; LVH  left ventricular hypertrophy; NYHA  New York Heart Association; PTCA
 percutaneous transluminal coronary angioplasty.
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prognostic importance of assessing LVH in those with
CAD. We found that the identification of LVH by echo-
cardiography had similar prognostic importance to knowing
a patient’s LV ejection fraction (Table 2). Contrary to prior
reports and speculation, however, we found that the RR of
LVH was almost identical in blacks and whites and women
and men. Differences between our results and prior studies
may be due to our more racially diverse population and our
inclusion of only patients with known coronary disease.
Although the RR of LVH was constant among patient
subgroups, racial and gender differences in disease preva-
lence of LVH may have important prognostic implications.
Specifically, multiple studies have reported that blacks and
women have higher mortality with coronary disease than
their counterparts (1,18–20). However, these prior studies
had not considered the influence of LVH. We found much
of the race and gender differences in prognosis accounted
for by the higher prevalence of LVH among blacks and
women.
Biologic influence of LVH on prognosis. Left ventricular
hypertrophy has multiple potential mechanisms for detri-
mental end organ sequelae. Activation of the renin-
angiotensin system leads to cardiac hypertrophy and LVH
(21). Angiotensin II has been shown to induce vasoconstric-
tion by local release of norepinephrine (22,23). Angiotensin
II has also been directly linked to the coagulation and
fibrinolytic pathways and vascular smooth muscle prolifer-
ation and thus progression of atherosclerosis (24,25).
Therefore, angiotensin II may be the common mediator
explaining the strong association of LVH with CAD.
Left ventricular hypertrophy may also increase the risk of
death in those patients having coronary disease. Studies
have demonstrated that LVH is associated with increases in
whole-blood viscosity, white blood cell counts, and plasma
fibrinogen levels, all increasing patients’ likelihood for a
coronary event (26,27). Additionally, the Framingham
Heart Study showed that hypertensive patients with LVH
are at increased risk of sudden arrhythmic death (4,28). Of
patients with LVH 92% will demonstrate re-entry rhythms
in response to programmed ventricular stimulation versus
17% in those without, suggesting an anatomic substrate for
ventricular arrhythmias (29).
Although the prognostic implications of LVH were clear,
less had been understood regarding effective treatment for
LVH. Proposed therapies include diuretics, calcium-
channel blockers, beta-blockers, angiotensin-converting en-
Table 2. Predictors of All-Cause Three-Year Mortality
Variable
All-Cause Mortality
Wald
Chi-Squared HR (95% CI)
Age* 76 1.30 (1.26–1.44)
Coronary artery disease† 52 1.58 (1.34–1.86)
Left ventricular mass index 36 1.56 (1.35–1.80)
Ejection fraction‡ 34 1.16 (1.11–1.22)
Diabetes 19 1.37 (1.19–1.58)
Chronic obstructive pulmonary
disease
17 1.51 (1.24–1.85)
Congestive heart failure 15 1.09 (1.05–1.15)
Peripheral vascular disease 15 1.35 (1.16–1.57)
Mitral insufficiency 8 1.33 (1.10–1.61)
Black race 1 1.10 (0.93–1.31)
Female gender 0.9 0.93 (0.81–1.08)
*Relative risk per decade of life increase. †Relative risk associated with single-vessel
disease versus multivessel disease. ‡Relative risk for ejection fraction expressed as a
10% decrease. All other variables are categorical.
CI  confidence interval; HR  hazard ratio.
Figure 1. Survival curves for patients with and without left ventricular
(LV) hypertrophy showing unadjusted (A) and adjusted (B) comparisons of
the two groups. Numbers at the bottom of the plots show the number of
patients at risk at 0 and 5 years of follow-up. H  LV mass high; N  LV
mass normal.
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zyme inhibitors, and angiotensin II blockers. However, the
recently completed Losartan Intervention For End point
reduction in hypertension (LIFE) trial provided some com-
parative data, randomizing patients with hypertension and
LVH to an angiotensin II blocker (losartan) versus a
beta-blocker (atenolol). The study found that those treated
with losartan had greater regression in the LVH and 13%
lower RR for acute myocardial infarction, stroke, and death
than those treated with a beta-blocker (30).
Study limitations. Our study was limited to those with
CAD and does not address LVH in those without CAD.
Our study was retrospective and thus limited to those patients
undergoing echocardiography and catheterization, a popula-
tion that is generally sicker than patients undergoing catheter-
ization alone. Serial LVH measurements were not obtained
and there were no data on patients’ medication profiles.
Conclusions and clinical application. Our study suggests
that current CAD risk stratification algorithms should be
Figure 2. Survival curves for patients with and without left ventricular
(LV) hypertrophy showing black (A) and white (B) patients adjusted for
demographic and clinical characteristics. Numbers at the bottom of the
plots show the number at risk at 0 and 5 years of follow-up. H  LV mass
high; N  LV mass normal.
Figure 3. Survival curves for patients with and without left ventricular
(LV) hypertrophy showing female (A) and male (B) patients adjusted for
demographic and clinical characteristics. Numbers at the bottom of the
plots show the number of patients at risk at 0 and 5 years of follow-up.
H  LV mass high; N  LV mass normal.
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re-evaluated to consider the strong incremental prognostic
influence of LVH. Assessment of LVH can significantly
improve assessment of an individual patient’s long-term
prognosis. Unfortunately, LVH is common in patients with
coronary disease, particularly in blacks and women, and may
partially explain poor prognosis in these latter groups.
Primary and secondary prevention of LVH through appro-
priate pharmacologic therapy is indicated. Further studies,
however, are needed to determine which form of treatment
is most effective and whether treatment selection varies as a
function of patient race or gender.
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